Background
==========

The world is facing a demographical shift in which the older population will increase. It is thus fair to assume that the prevalence of disorders that are common among older persons will also increase. Studies have shown that mental disorders are prevalent among the old \[[@B1]-[@B3]\], even when dementia disorders are excluded \[[@B4],[@B5]\]. The treatment of mental disorders (i.e. affective, psychotic and anxiety disorders) in older persons is a complex task and can be affected by a variety of factors, including pharmacokinetic and pharmacodynamic changes related to age, influences of concurrent disorders and possible adverse drug reactions. Although the risk of adverse drug reactions increases with age, drug treatment is common among older persons, both nationally \[[@B6]\] and internationally \[[@B7]\]. As older persons are often treated for several conditions besides mental disorders, the possibility for unwanted drug interactions is increased in this age group. Indeed, several studies have reported that older persons are subjected to polypharmacy and inappropriate drug use \[[@B8]-[@B10]\], and that many hospitalizations occur due to drug related problems \[[@B11]\].

The treatment of mental disorders often involves several different physicians, raising questions about who ultimately carries the responsibility for the adequacy and quality of the combined pharmaceutical regime. In addition, the time allocated to mental health issues during consultations with physicians is generally low \[[@B12]\] and the combination of several prescribers commonly entails more drugs and lower overall quality of care \[[@B13]\]. At present, very little time (at most two weeks) is allocated to the field of geriatrics during the training to become a licensed physician in Sweden \[[@B14]\]. Specialists in geriatrics and psychiatry represent approximately 2% and 6%, respectively, of the licensed physicians in Sweden, while physicians with specialist education in general medicine (general practitioners, GPs) represent 18% \[[@B15]\]. Hence, there is an obvious lack of physicians with specialized skills in treating older persons with mental disorders.

GPs providing care for older persons have reported feeling insecure when required to surpass their own competence, as well as a lack of communication with other physicians and specialists \[[@B16]\]; these factors can negatively impact the treatment and care given to older persons with mental disorders. Studies have demonstrated that treatment by geriatric teams reduces mortality \[[@B17],[@B18]\] and increases the possibility for older persons to remain at home \[[@B19],[@B20]\]. Although the particular knowledge that geriatricians acquire is vital in providing older persons with adequate treatment and care, health care personnel tend to prefer interdisciplinary teams comprising different medical specialties when treating and caring for older persons with or without mental disorders \[[@B21],[@B22]\]. Psychiatrists in particular contribute important knowledge on mental health and, as they generally hold more positive professional attitudes towards people with mental disorders such as schizophrenia \[[@B23]\], they would preferably be included in such a team.

The current situation for older persons with mental disorders has scarcely been studied and questions have been raised as to whether or not older persons with extensive needs receive adequate care and treatment. In order to facilitate the improvement of treatment and to reduce possible adverse drug reactions among older persons with mental disorders, it is important to evaluate the amounts and types of drugs older persons are being prescribed and which medical specialties their prescribers hold.

Aim
---

This study aimed to evaluate the prescription of drugs for mental disorders to older persons (≥65 years) in Sweden during the three-year period from 2006 to 2008, focusing on the medical specialties among the prescribing physicians and the amount of drugs prescribed to older men and women.

Methods
=======

Study population
----------------

All persons in Sweden aged 65 years and older were included in this analysis if they had received one or more registered prescriptions for drugs for mental disorders included in the International Classification of Diseases, version 10 (ICD-10) F20-F42 \[[@B24]\] during 2006, 2007 or 2008. A total of 188 024 individuals, who together received 2 013 079 dispensed drugs for mental disorders during the years 2006, 2007 and 2008, were included in the study.

Data measurement
----------------

The Swedish Prescribed Drug Register (SPDR) from the Swedish National Board of Health and Welfare was the source for the data included in the analysis. All personal information was replaced with serial numbers. The variables included were age (65 years and older), sex, ATC codes (level 5; chemical substance), prescribing and dispensing dates, as well as the specialist codes for the prescribers.

Data collection and analysis
----------------------------

The SPDR was used to explore the prescription of drugs for mental disorders to older persons. Complete information about the drugs dispensed at national pharmacies is included in the register. As social security numbers were introduced to the register in 2005, the analyses were carried out using data from 2006 to 2008. Older persons receiving prescriptions for drugs indicated or recommended in the Swedish Medicines Information portal \[[@B25]-[@B28]\] for use in psychotic (F20-29, ICD-10), affective (F30-39, ICD-10) and anxiety (F41-42, ICD-10) disorders, Chapter V, ICD-10 \[[@B24]\] were included in the analysis. The Anatomical Therapeutic Chemical Classification (ATC) codes, level 5, were subsequently applied (see Table [1](#T1){ref-type="table"}). Drugs intended for use in dementia disorders (ICD-10: F00-03; ATC: N06DA02-04, N06DX01) or recommended as firsthand choice in dementia disorders (ATC: N05AA-AX, N05CF-CM, N06AB, N06DA-DX) have been excluded to avoid analyzing persons with diffuse symptoms that could be classified as either mental disorders or dementia disorders. All prescriptions filled and dispensed during the three-year period were included in the analysis.

###### 

Evaluated disorders from International Classification of Diseases version 10 (ICD-10), Chapter V Mental and behavioral disorders: F20-29 (schizophrenia, schizotypal and delusional disorders), F30-39 (affective disorders), F41 (other anxiety disorders) and F42 (obsessive-compulsive disorders); the applied ATC codes level 5 and the corresponding chemical substances included in the study

  **ATC level 5**   **Chemical substance**    **F20-29**   **F30-39**   **F41**   **F42**
  ----------------- ------------------------ ------------ ------------ --------- ---------
  N03AE01           Clonazepam                                                       X
  N03AF01           Carbamazepin                               X                      
  N03AG01           Valproic acid                              X                      
  N03AX09           Lamotrigine                                X                      
  N03AX16           Pregabalin                                             X          
  N04BC05           Pramipexole                                X                      
  N05BA01           Diazepam                      X            X           X          
  N05BA04           Oxazepam                      X            X           X          
  N05BA06           Lorazepam                     X            X           X          
  N05BA12           Alprazolam                    X            X           X          
  N05BE01           Buspirone                                  X           X          
  N06AA04           Clomipramine                  X                        X         X
  N06AA06           Trimipramine                  X            X                      
  N06AA09           Amitriptyline                 X            X                      
  N06AA10           Nortriptyline                 X            X                      
  N06AA21           Maprotiline                   X            X                      
  N06AG02           Moclobemide                                X                      
  N06AX02           Tryptophan                                 X                      
  N06AX03           Mianserin                                  X                      
  N06AX11           Mirtazapine                                X                      
  N06AX12           Bupropion                                  X                      
  N06AX16           Venlafaxine                                X                      
  N06AX18           Reboxetin                                  X           X          
  N06AX21           Duloxetine                                 X                      
  N06BA07           Modafinil                                  X                      

The Swedish system for attaining a specialist degree as a physician includes at least five years of full-time specialization education following undergraduate studies and involves working under supervision and attending complementary education. During the years 2006, 2007 and 2008 there were a total of 62 different specialties possible for physicians, and a given physician may hold several different specialties. In the data analyses, the specialist categories were divided into four groups: general practitioners (GPs), geriatricians, psychiatrists (including specialist education in forensic psychiatry as well as children and young peoples' psychiatry) and "other specialists" comprising all other specialists. Licensed physicians with no specialist education were analyzed separately. Descriptive univariate analyses with frequency distribution and 95% CI were carried out using IBM SPSS Statistics 19.0 for Windows (SPSS Inc. an IBM company, 1989--2010).

The regional ethics board in Uppsala, Sweden critically and ethically revised and approved this study to be compliant with the Helsinki Declaration \[[@B29]\] (Reference number 2008/345/2).

Results
=======

On average, 7% of the older population was prescribed drugs for mental disorders during the years 2006, 2007 and 2008 (see Table [2](#T2){ref-type="table"}), with more than one-half million prescriptions dispensed to the older population at national pharmacies each year. Women constituted two-thirds and men one-third of the older population receiving these drugs.

###### 

**Characteristics of the study population: number of persons in the older population and number of persons (*n*) receiving dispensed drugs for mental disorders (MD) (ICD-10: F20-F42), mean age with standard deviation (SD), percentage men and women in the study population, and total number of dispensed drugs for mental disorders**

                                             **2006**     **2007**     **2008**
  ---------------------------------------- ------------ ------------ ------------
  Older population, total (*n*)             1 581 437    1 608 413    1 645 081
  Persons receiving drugs for MD (*n*)       104 441      106 665      108 306
  Mean age (years) (SD)                     77.8 (7.8)   77.8 (7.8)   77.7 (7.9)
  Men/Women (%)                               35/65        35/65        36/64
  Total number of dispensed drugs for MD     639 841      671 071      702 167

Drugs corresponding to 25 different ATC codes, level 5, were dispensed to older persons (≥65) in Sweden from 2006 to 2008, all of which were included in the analysis (see Table [3](#T3){ref-type="table"}). Each ATC code corresponds to one specific chemical substance and may have several brand names. The most commonly prescribed and dispensed chemical substances during each of the three years were the benzodiazepines oxazepam and diazepam (anxiolytics), as well as the non-selective monoamine reuptake inhibitor amitriptyline (antidepressant). The amount and frequency of prescriptions for many of these chemical substances changed over the course of the three years: a decrease was seen in prescriptions for 48% of the substances and an increase for 24%.

###### 

Frequency of ATC codes prescribed to the study population

  **ATC**   **Chem. Sub.**   **ICD**        **2006**   **2007**   **2008**                                                    
  --------- ---------------- -------------- ---------- ---------- ------------- ------- ------- ------------- ------- ------- -------------
  N03AE01   Clonazepam       42             1015       0.97       0.91-1.03     1082    1.01    0.95-1.07     1097    1.01    0.95-1.07
  N03AF01   Carbamazepin     31             7917       7.58       7.42-7.74     7877    7.38    7.23-7.54     7814    7.21    7.06-7.37
  N03AG01   Valproic acid    31             2220       2.13       2.04-2.21     2308    2.16    2.08-2.25     2377    2.19    2.11-2.28
  N03AX09   Lamotrigine      31             1259       1.21       1.14-1.27     1436    1.35    1.28-1.42     1691    1.56    1.49-1.64
  N03AX16   Pregabalin       41             2641       2.53       2.43-2.62     3982    3.73    3.62-2.85     5231    4.83    4.70-4.96
  N04BC05   Pramipexole      30-39          6188       5.92       5.78-6.07     7807    7.32    7.16-7.48     9093    8.40    8.23-8.56
  N05BA01   Diazepam         20-39, 41      20075      19.22      18.98-19.46   19315   18.11   17.88-18.34   18477   17.06   16.84-17.28
  N05BA04   Oxazepam         20-39, 41      41521      39.76      39.46-40.05   41725   39.12   38.82-39.41   41226   38.06   37.78-38.35
  N05BA06   Lorazepam        20-39, 41      1175       1.13       1.06-1.19     1119    1.05    0.99-1.11     1093    1.01    0.95-1.07
  N05BA12   Alprazolam       20-39, 41      3992       3.82       3.71-3.94     3910    3.67    3.55-3.78     3819    3.53    3.42-3.64
  N05BE01   Buspirone        30-39, 41      473        0.45       0.41-0.49     422     0.40    0.36-0.43     401     0.37    0.33-0.41
  N06AA04   Clomipramine     20-29, 41-42   2841       2.72       2.62-2.82     2827    2.65    2.55-2.75     2739    2.53    2.44-2.62
  N06AA06   Trimipramine     20-39          342        0.33       0.29-0.36     196     0.18    0.16-0.21     48      0.04    0.03-0.06
  N06AA09   Amitriptyline    20-39          11914      11.41      11.21-11.60   11907   11.16   10.97-11.35   12275   11.33   11.14-11.52
  N06AA10   Nortriptyline    20-39          381        0.36       0.33-0.40     367     0.34    0.31-0.38     307     0.28    0.25-0.32
  N06AA21   Maprotiline      20-39          413        0.40       0.36-0.43     342     0.32    0.29-0.35     322     0.30    0.26-0.33
  N06AG02   Moclobemide      30-39          186        0.18       0.15-0.20     167     0.16    0.13-0.18     152     0.14    0.12-0.16
  N06AX02   Tryptophan       30-39          36         0.03       0.02-0.05     37      0.03    0.02-0.05     28      0.03    0.02-0.04
  N06AX03   Mianserin        30-39          1575       1.51       1.43-1.58     1527    1.43    1.36-1.50     1523    1.41    1.34-1.48
  N06AX11   Mirtazapine      30-39          9296       8.90       8.73-9.07     10581   9.92    9.74-10.10    11500   10.62   10.43-10.80
  N06AX12   Bupropion        30-39          1552       1.49       1.31-1.56     1264    1.19    1.12-1.25     838     0.77    0.72-0.83
  N06AX16   Venlafaxine      30-39          3792       3.63       3.52-3.74     3848    3.61    3.50-3.72     4126    3.81    3.70-3.92
  N06AX18   Reboxetin        30-39, 41      91         0.09       0.07-0.11     74      0.07    0.05-0.09     91      0.08    0.07-0.10
  N06AX21   Duloxetine       30-39          1480       1.42       1.35-1.49     1602    1.50    1.43-1.57     2036    1.88    1.80-1.96
  N06BA07   Modafinil        30-39          95         0.09       0.07-0.11     125     0.12    0.10-0.14     136     0.13    0.10-0.15

ATC codes (ATC), the corresponding chemical substances (Chem. Sub.) and ICD-10 codes F20-42 (ICD) (Chapter V Mental and behavioral disorders) to which the ATC codes can be prescribed, number of older persons (*n*) prescribed each of ATC-codes level 5 and percentage (%) of the older population being prescribed drugs for mental disorders, with 95% CI, during 2006, 2007 and 2008

On average, during the period from 2006 to 2008, two-thirds (65%) of the prescribing physicians were GPs (see Figure [1](#F1){ref-type="fig"}), whereas approximately 4% were geriatricians and 3% psychiatrists. Approximately 14% of the prescribers were physicians with specialist education other than the aforementioned, the majority of whom were specialists in internal medicine, cardiology or neurology. Physicians without any specialist education corresponded to 14% of the prescribers. The tendency of GPs and geriatricians to hand out prescriptions increased with the age of the patient, while the amount of prescriptions from psychiatrists, other specialists, and physicians with no specialist education decreased with age.

![**Percentage of physicians with specialist education in geriatrics (GER), psychiatry (PSYCH), general practitioners (GP), other specialists (OTH) or physicians without specialist education (WO) prescribing drugs for mental disorders (Y-axis) to older persons, in 5-year age brackets (X-axis).** Data are presented as average values for the 3-year period (2006 to 2008) with SEM.](1471-244X-12-197-1){#F1}

Among the dispensed substances, the most commonly prescribed were two benzodiazepine derivatives and one non-selective monoamine reuptake inhibitor (see Table [4](#T4){ref-type="table"}). During 2006 to 2008, an average of 39% of the study population was prescribed the anxiolytic oxazepam, while approximately 18% was prescribed diazepam. The antidepressant amitriptyline was prescribed to 11% of the study population yearly, from 2006 to 2008. GPs represented the category of physicians that most commonly prescribed these top three ATC codes. While men and women both received equal amounts of prescriptions from geriatricians and psychiatrists, men received prescriptions from other specialists and physicians with no specialist education to a higher extent than women.

###### 

**The three most commonly prescribed drugs (classification, ATC-code level 5 and chemical substance) for mental disorders (ICD-10) from 2006 to 2008: number (*n*) of and percentage (%), with 95% CI, of older persons (men and women) prescribed drugs for mental disorders by specialists in geriatrics (GER), psychiatry (PSYCH), general practitioners (GP), other specialists (OTH) or by physicians without specialist education (WO)**

  **Classification ATC Chem. Sub.**            **ICD-10**   **Specialists**   **Patients' sex**   **2006**   **2007**   **2008**                                                    
  -------------------------------------------- ------------ ----------------- ------------------- ---------- ---------- ----------- ------- --------- ----------- ------- --------- -----------
  Benzodiazepine derivative                    F20-39, 41   GER               Men                 470        4.0        3.6-4.3     492     4.1       3.7-4.4     551     4.6       4.2-4.9
                                                            Women             1218                4.1        3.9-4.3    1302        4.4     4.2-4.6   1378        4.7     4.5-5.0   
  N05BA04                                                   PSYCH             Men                 394        3.3        3.0-3.7     405     3.4       3.0-3.7     413     3.4       3.1-3.8
  Oxazepam                                                                    Women               815        2.7        2.6-2.9     785     2.6       2.5-2.8     793     2.7       2.5-2.9
                                                            GP                Men                 8042       68.3       67.4-69.1   8285    68.6      67.7-69.4   8148    67.7      66.8-68.5
                                                                              Women               22132      74.4       73.9-74.9   22099   74.6      74.1-75.0   21655   74.2      73.7-74.7
                                                            OTH               Men                 1613       13.7       13.1-14.3   1636    13.5      12.9-14.1   1677    13.9      13.3-14.5
                                                                              Women               2929       9.8        9.5-10.2    2905    9.8       9.5-10.1    2816    9.6       9.3-10.0
                                                            WO                Men                 1591       13.5       12.9-14.1   1621    13.4      12.8-14.0   1618    13.4      12.8-14.0
                                                                              Women               3462       11.6       11.3-12.0   3462    11.7      11.3-12.0   3419    11.7      11.3-12.1
  Benzodiazepine derivative                    F20-39, 41   GER               Men                 262        3.5        3.1-3.9     233     3.2       2.8-3.6     247     3.6       3.2-4.0
                                                            Women             477                 3.8        3.4-4.1    485         4.0     3.7-4.4   481         4.1     3.8-4.5   
  N05BA01                                                   PSYCH             Men                 290        3.9        3.5-4.3     295     4.0       3.6-4.5     280     4.1       3.6-4.6
  Diazepam                                                                    Women               415        3.3        3.0-3.6     411     3.4       3.1-3.7     422     3.6       3.3-4.0
                                                            GP                Men                 4820       64.6       63.6-65.7   4799    65.8      64.7-66.9   4501    65.7      64.6-66.8
                                                                              Women               9024       71.5       70.7-72.3   8577    71.4      70.6-72.2   8324    71.6      70.8-72.4
                                                            OTH               Men                 1374       18.4       17.5-19.3   1263    17.3      16.4-18.2   1145    16.7      15.8-17.6
                                                                              Women               1727       13.7       13.1-14.3   1606    13.4      12.8-14.0   1510    13.0      12.4-13.6
                                                            WO                Men                 902        12.1       11.4-12.8   886     12.1      11.4-12.9   854     12.5      11.7-13.2
                                                                              Women               1308       10.4       9.8-10.9    1280    10.7      10.1-11.2   1239    10.7      10.2-11.2
  Non-selective monoamine reuptake inhibitor   F20-39       GER               Men                 125        3.6        3.0-4.3     107     3.2       2.6-3.7     106     2.9       2.4-3.5
                                                            Women             269                 3.2        2.8-3.5    280         3.3     2.9-3.7   276         3.2     2.8-3.6   
                                               PSYCH        Men               101                 2.9        2.4-3.5    95          2.8     2.2-3.4   97          2.7     2.2-3.2   
  N06AA09                                                                     Women               269        3.2        2.8-3.5     251     2.9       2.6-3.3     254     2.9       2.6-3.3
  Amitriptyline                                             GP                Men                 2133       62.1       60.5-63.8   2172    64.0      62.4-65.6   2276    63.1      61.5-64.7
                                                                              Women               5868       69.2       68.2-70.2   5957    70.0      69.0-70.9   6082    70.2      69.2-71.1
                                                            OTH               Men                 585        17.0       15.8-18.3   553     16.3      15.1-17.5   624     17.3      16.1-18.5
                                                                              Women               1038       12.2       11.5-12.9   1100    12.9      12.2-13.6   1133    13.1      12.4-13.8
                                                            WO                Men                 568        16.5       15.2-17.8   531     15.7      14.4-16.9   569     15.8      14.6-17.0
                                                                              Women               1254       14.8       14.0-15.5   1143    13.4      12.7-14.1   1145    13.2      12.5-13.9

Each year approximately 15% of the older population received two or more substances for mental disorders on one or recurrent occasions during the years 2006, 2007 and 2008 (see Table [5](#T5){ref-type="table"}). The prescription of one chemical substance tended to decrease, while there was a minor increase in the prescription of two and three chemical substances during the three years.

###### 

**Number (*n*) and percentage (%) of the older population age ≥65 in Sweden receiving prescriptions for one to eight chemical substances for mental disorders, during the years 2006, 2007 and 2008**

  **ATC**   **2006**   **2007**   **2008**                                                                                                                                   
  --------- ---------- ---------- ---------- --------- ------- --------- -------- --------- ------- --------- ------- --------- -------- --------- ------- --------- ------- ---------
  1         89046      (85.3)     31380      (86.5)    57666   (84.6)    90369    (84.7)    32314   (85.8)    58055   (84.1)    91368    (84.4)    32960   (85.6)    58407   (83.7)
  2         13191      (12.6)     4175       (11.5)    9015    (13.2)    13871    (13.0)    4550    (12.1)    9320    (13.5)    14308    (13.2)    4695    (12.2)    9613    (13.8)
  3         1848       (1.77)     599        (1.65)    1249    (1.83)    2037     (1.91)    662     (1.76)    1375    (1.99)    2160     (1.99)    688     (1.79)    1472    (2.11)
  4         295        (0.28)     81         (0.22)    214     (0.31)    328      (0.31)    102     (0.27)    226     (0.33)    387      (0.36)    136     (0.35)    251     (0.36)
  5         51         (0.05)     19         (0.05)    32      (0.05)    49       (0.05)    11      (0.03)    38      (0.06)    72       (0.07)    24      (0.06)    48      (0.07)
  6         7          (0.01)     3          (0.01)    4       (0.01)    9        (0.01)    4       (0.01)    5       (0.01)    9        (0.01)    6       (0.02)    3       (0.00)
  7         2          (0.00)     1          (0.00)    1       (0.00)    2        (0.00)                      2       (0.00)    2        (0.00)    2       (0.01)             
  8         1          (0.00)     1          (0.00)                                                                                                                           
  Total     104441     \(100\)    36259      \(100\)   68181   \(100\)   106665   \(100\)   37643   \(100\)   69021   \(100\)   108306   \(100\)   38511   \(100\)   69794   \(100\)

GPs prescribed drugs for mental disorders to both women and men to a high extent during all three years (see Figure [2](#F2){ref-type="fig"}). In 2006 the prescriptions written by geriatricians to women increased with increasing number of substances, while their prescribing to men was consistently low. The prescriptions written by psychiatrists to both men and women increased with increasing number of substances.

![Percentage of physicians with specialist education in geriatrics (GER), psychiatry (PSYCH), general practitioners (GP), other specialists (OTH) or physicians without specialist education (WO) prescribing one or more ATC codes, level 5 (chemical substance) for mental disorders to women (a, c, e) and men (b, d, f) during the years 2006, 2007 and 2008.](1471-244X-12-197-2){#F2}

In 2007, both men and women were prescribed drugs from geriatricians and from physicians with no specialist education to a low extent. The prescriptions written by psychiatrists to women increased with increasing number of substances, while their prescribing to men decreased with more than five substances. In the year 2008, prescriptions by psychiatrists increased with increasing number of substances for both men and women.

Discussion
==========

To our knowledge no other studies have evaluated the prescription of drugs for older persons with mental disorders other than dementia disorders, with a particular focus on the medical specialty of the prescribing physician. This study shows that GPs represented the main prescribers, whereas geriatricians and psychiatrists rarely prescribed drugs to older persons.

The study includes all older persons (≥65) in Sweden who received drugs dispensed at national pharmacies and thus includes the vast majority of the older population. The prevalence of prescriptions for drugs for mental disorders corresponds to approximately 7% of the older population in Sweden \[[@B4]\]. In fact, each year, more than half a million such prescriptions are dispensed to the older population, and the most commonly prescribed drugs are anxiolytics (benzodiazepines: oxazepam and diazepam) and tricyclic antidepressants (amitriptyline). Although previous studies on potentially inappropriate drugs for older persons suggested that benzodiazepines and tricyclic antidepressants are associated with a high risk of adverse effects and should be replaced with safer alternative drugs or therapies \[[@B30],[@B31]\], the present study indicates that the use of benzodiazepines and tricyclic antidepressants was frequent. Approximately 60% of the older population was prescribed benzodiazepines, and only a minor decrease was observed over the course of the study. Furthermore, antidepressants such as mirtazapine are shown to involve high risk for adverse effects, including stroke or attempted suicide \[[@B32]\], and despite its association with adverse effects in older persons, prescriptions for mirtazapine tended to increase over the years. These findings highlight the clinical relevance of thoroughly and regularly evaluating the continuous treatment of older persons.

Whereas approximately 85% of the older population received only one chemical substance intended for treating mental disorders, approximately 15% received two or more substances. Although this finding per se does not indicate polypharmacy or risk for adverse drug reactions, previous studies of the use of multiple drugs in older persons suggested that it may result in inferior self-rated health \[[@B33]\] and increased depressive symptoms \[[@B34]\].

The importance of expertise in geriatrics, gerontology and psychiatry when treating older persons in general and those with mental disorders in particular has been debated \[[@B35]-[@B37]\]. Physicians without specialist education prescribed all types of psychotropics, across all age groups. As licensed physicians without specialist education in Sweden have undergone at most two weeks of training and education in geriatrics \[[@B14]\], their prescribing behavior may be detrimental to the quality and adequacy of the treatment provided to older persons with mental disorders. The present study does, however, conclude that the majority of prescriptions for drugs for mental disorders were given by GPs, perhaps not surprising as GPs represent the majority of physicians in Sweden. GPs are recognized as an important part of psychiatric care \[[@B38]\]. In the present study, the tendency of GPs to prescribe drugs for mental disorders increased with the age of the patient. This corresponds to a previous study showing that although GPs are aware of the advantages of reducing the prescription of psychotropic drugs, they struggle to convince their older patients of the benefits of this \[[@B39]\].

A previous study has shown that licensed physicians, other than psychiatrists, inaccurately diagnose mental disorders in older persons, and consequently prescribe inappropriate drugs \[[@B40]\]. Improved knowledge of geriatric psychiatry, including alternative treatments for older persons with mental disorders, would likely lead to the decrease in inappropriate prescription of drugs. However, although previous research has provided strong evidence on how to improve the care of older persons with mental disorders, translation into practice is rare \[[@B41],[@B42]\]. Older persons with mental disorders are consequently subjected to lack of evidence-based care. To facilitate the translation of research into practice and to meet the need for specialists in geriatric psychiatry, it is essential to launch new extended educational programs for geriatricians and psychiatrists, as well as geriatric psychiatrists \[[@B43]\]. At present, only 60% trained geriatricians in Sweden continue to work with older persons throughout their careers \[[@B14]\]; low numbers of geriatricians indicates that most older persons are treated by other specialists and could explain the relatively low percentage of drugs prescribed by geriatricians. The proportion of prescriptions from geriatricians is overall low, but does increase up to 10% with increasing age of the patients; this may reflect the tendency of older persons to be treated by geriatricians as they approach 100 years of age. The proportion of prescriptions written by psychiatrists is also remarkably low: only 5% of the older persons aged 65 to 69 received prescriptions from psychiatrists and this percentage decreased further with increasing age.

The present study shows that women who are dispensed several substances tend to receive their prescriptions from geriatricians and psychiatrists to a higher extent than men. It has been demonstrated that women in old age are more likely to be affected by mental disorders \[[@B44]\] and receive mental health care than men \[[@B45]\]; this may have increased the awareness of mental health issues among older women and led to more frequent referrals of women with mental disorders to specialists such as geriatricians and psychiatrists. This supports the necessity of continuing the discussion on gender differences in old age psychiatry and it becomes evident that new and improved approaches in the care of older persons are of utmost importance for providing the older population with adequate care and treatment.

Given the complexity and challenges entailed in providing care for older persons, an increase in the number of geriatric specialists with improved competence in psychiatry or the involvement of teams of different specialists may positively contribute to improving the quality of care. Communication between GPs and other specialists is vital for improving the care and treatment of older persons in general \[[@B46]\] as well as older persons with mental disorders \[[@B47],[@B48]\]. In order to assist healthcare personnel in providing the highest quality care to older persons with mental disorders, it is necessary to provide appropriate and effective drug treatment.

Strengths and limitations
-------------------------

The SPDR includes all prescriptions dispensed at national pharmacies and consequently includes the vast majority of the population in Sweden. The study population therefore consisted of approximately 200 000 older persons, which must be considered as a strength of this study. Nonetheless, this study had some limitations. Drugs that could be used for dementia disorders have been excluded which may have led to some types of selection bias. Due to the lack of diagnoses in the register, drug use was used as a proxy for diagnoses. Consequently, it is likely that some of the drugs that were excluded due to plausible use for dementia disorders may have been prescribed for an actual diagnosis and treatment for a mental disorder and should have been included in the study (diagnosis bias). The lack of diagnoses is a crucial limitation that may have decreased the validity of the results. To counteract this bias as far as possible, the treatment guidelines and recommendations set for each year of the study were thoroughly scrutinized and each disorder and ATC code was evaluated with the help of practicing psychiatrists in order to minimize inaccuracy. Drugs recommended as firsthand options for treating dementia disorders or symptoms during the years of the study were excluded to facilitate studying mental disorders besides dementia disorders. Consequently, this brought an unfortunate exclusion of SSRIs and antipsychotics. In addition, with the register lacking diagnoses the included drugs may have been prescribed on indications other than mental disorders; tricyclic antidepressants may be prescribed for e.g. neuropathic pain rather than depression. However, as this study aimed to present what medical specialties the prescribers hold rather than the prevalence of certain disorders, each disorder and connected drugs, including all antidepressants and antipsychotics, will be further analyzed in future studies.

With the character of the national register generalizations to older populations outside Sweden must be made with consideration. One important limitation is that the register does not include diagnoses. As a result of this limitation the interpretation of the results with respect to diagnoses and disorders may affect the outcome as the differences in prescribing rates by different specialists could be altered if diagnoses were to be included. However, the register does deliver reliable information about the competences of the prescribing physicians. Questions regarding alternative therapies and non-pharmacological treatment were not within the scope of this study. However, it would be of interest to study the frequency of prescriptions for non-pharmacological treatments by the various specialist categories. In addition, whether or not the prescribing rates by different specialists differ depending on the characteristics of the drug remain unclear and consequently future studies will include studying the prescribing rates when including e.g. SSRIs in the analyses. Possibly the prescribing differences between specialists and physicians without specialist education depend on specialists recurring more frequently to other classes of drugs different from those used by physicians without specialist education. Hence future studies may answer questions as to whether or not psychiatrists and/or geriatricians prescribe alternative treatments to a greater extent than other specialists or, alternatively, if the degree of patient contact with these specialists is overall low. In future studies we will also examine subsamples of the population and their prescriptions will be further scrutinized with respect to daily doses and comparisons to the general recommendations in order to further elucidate the subject.

Conclusions
===========

The majority of prescriptions of drugs for mental disorders were made by GPs and not by specialists on disorders affecting the older population (geriatricians) or specialists on mental disorders (psychiatrists). The most commonly prescribed drugs were the benzodiazepines oxazepam and diazepam, as well as the tricyclic antidepressant amitriptyline, despite the fact that clinical guidelines do not recommend these medications for regular use in older persons. Approximately 15% of the older population receiving drugs for mental disorders received several substances. The results highlight the importance of regularly evaluating pharmaceutical prescriptions to older persons and raise questions about whether the involvement of more geriatric or psychiatric specialists would improve overall care.
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